LPCN Lipocine Inc.
Price Chart
Executive Summary
Lipocine filed an 8-K announcing a virtual KOL event on June 12, 2026, to discuss unmet needs in postpartum depression and Phase 3 topline results for LPCN 1154 (oral brexanolone). The event features prominent KOLs and management, but no new clinical data, regulatory milestones, or financial details are disclosed in the filing — the company is reiterating prior Phase 3 subgroup efficacy and safety data. This is a routine investor-awareness event with no material new information, making it neutral for traders.
Actionable Insight
Monitor the June 12 KOL event for any incremental commentary on the LPCN 1154 regulatory path or partnership strategy. Without new data or a clear NDA timeline, this filing does not change the stock's risk/reward — any price move is likely noise. Watch for a subsequent 8-K if material regulatory developments follow.
Key Facts
- Virtual KOL event on June 12, 2026, at 11:00 AM Eastern Time
- Event will review LPCN 1154 Phase 3 topline results and PPD treatment landscape
- Phase 3 trial showed efficacy in a subgroup analysis excluding an epidemiologic outlier site
- 100% of participants completed dosing; no treatment-related serious adverse events
- LPCN 1154 is not yet FDA approved
- No new financial data, regulatory submissions, or business developments announced
Financial Impact
No financial figures disclosed; event is a clinical/regulatory update
Risk Factors
- LPCN 1154 faces uncertain FDA approval path with Phase 3 data limited to a subgroup analysis
- No disclosed partnership or financing catalyst; cash runway not addressed in this filing
- Stock is highly speculative with $18M market cap and no approved revenue-generating products
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027209 |
| Exhibit: ex99-1.htm | 0001493152-26-027209 |
| Document: 0001493152-26-027209-index-headers.html | 0001493152-26-027209 |
| Document: 0001493152-26-027209-index.html | 0001493152-26-027209 |
| Document: 0001493152-26-027209.txt | 0001493152-26-027209 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
10d ago
|
8-K
| $2.21 $2.05 | ▼ −7.24% | ▼ −4.64% | $2.26 (+2.26%) |
|
May 26, 2026
19d ago
|
8-K
| $2.28 $2.26 | ▼ −0.88% | ▼ −1.43% | $2.26 (−0.88%) |
|
May 19, 2026
26d ago
|
8-K
| $2.20 $2.24 | ▲ +1.82% | ▲ +0.78% | $2.26 (+2.73%) |
|
May 18, 2026
27d ago
|
8-K
| $2.21 $2.20 | ▼ −0.45% | ▲ +0.20% | $2.26 (+2.26%) |
|
May 7, 2026
5w ago
|
8-K
| $2.39 $2.37 | ▲ +0.84% | ▲ +1.67% | $2.26 (+5.44%) |
|
Apr 21, 2026
7w ago
|
8-K
| $2.42 $2.35 | ▲ +2.89% | ▲ +2.50% | $2.26 (+6.61%) |
|
Apr 2, 2026
10w ago
|
8-K
| $2.05 $1.94 | ▼ −5.37% | ▼ −5.84% | $2.26 (+10.24%) |
|
Apr 2, 2026
10w ago
|
8-K
| $2.05 $1.94 | ▲ +5.37% | ▲ +5.84% | $2.26 (−10.24%) |
|
Mar 4, 2026
14w ago
|
8-K
| $8.19 $8.13 | ▼ −0.73% | ▲ +0.58% | $2.26 (−72.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access